Published mark
Vertex Pharmaceuticals
VERTEX PHARMACEUTICALS INC / MA
NASDAQ: VRTX. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:67a28a17-ff7a-4e42-a246-5086ab42eca9
- SEC CIK
- 0000875320
- Website
- www.vrtx.com Open
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Reshma Kewalramani, M.D.Chief Executive Officer and President
- Chair
- Jeffrey M. LeidenLead independent: Bruce Sachs
- Independent
- Not published11 directors published
- Published claims
- 527 distinct sources
- Evidence records
- 260 pinned
- Source conflicts
- 0None open
Built from 7 distinct sources and 26 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Jennifer Schneider seat on Vertex Pharmaceuticals, effective 2024-01-01.
EffectiveEffective Jan 1, 2024E7
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Executive Vice President, Chief Patient and External Affairs Officer | Amit K. Sachdev, J.D. | Not captured | unknown | Source reportedE14 |
| Executive Vice President, Chief Operating and Financial Officer | Charles F. Wagner, Jr. | Not captured | unknown | Source reportedE15 |
| Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer | Craig B. Thompson, M.D. | Not captured | unknown | Source reportedE16 |
| Executive Vice President, Chief Commercial Officer | Duncan J. McKechnie | Not captured | unknown | Source reportedE17 |
| Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Science and Manufacturing Operations | E. Morrow Morrey Atkinson, III, Ph.D. | Not captured | unknown | Source reportedE18 |
| Executive Vice President, Chief Legal Officer | Jonathan Biller, J.D. | Not captured | unknown | Source reportedE19 |
| Senior Vice President, Chief Accounting Officer | Kristen C. Ambrose, CPA | Not captured | unknown | Source reportedE20 |
| Executive Vice President, Chief Scientific Officer | Mark Bunnage, D.Phil | Not captured | unknown | Source reportedE21 |
| Executive Vice President, Chief Regulatory and Quality Officer | Ourania Nia Tatsis, Ph.D. | Not captured | unknown | Source reportedE22 |
| Chief Executive Officer and President | Reshma Kewalramani, M.D. | Not captured | unknown | Source reportedE23 |
Board of directors
Evidence11 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Alan Garber | Independence not published | 2017 | CGNCCGNC; Nominating and GovernanceNominating and Governance | Source reportedE4 |
| Bruce Sachs | Independence not publishedLead Independent | 1998 | None published | Source reportedE5 |
| Diana McKenzie | Independence not published | 2020 | AuditAudit; MDCC; CompensationCompensationMDCC | Source reportedE6 |
| Jeffrey M. Leiden | Independence not publishedChair | 2009 | None published | Source reportedE3 |
| Jennifer Schneider | Independence not published | 2024 | CompensationMDCCMDCC; Compensation | Source reportedE7 |
| Lloyd Carney | Independence not published | 2019 | AuditAudit; CGNC; Nominating and GovernanceCGNCNominating and Governance | Source reportedE8 |
| Michel Lagarde | Independence not published | 2023 | Audit | Source reportedE9 |
| Nancy Thornberry | Independence not published | 2023 | None published | Source reportedE10 |
| Reshma Kewalramani | Independence not published | 2020 | None published | Source reportedE11 |
| Sangeeta Bhatia | Independence not published | 2015 | CGNCCGNC; Nominating and GovernanceNominating and Governance | Source reportedE12 |
| Suketu Upadhyay | Independence not published | 2022 | AuditAudit; MDCC; CompensationCompensationMDCC | Source reportedE13 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Not published | Diana McKenzie, Lloyd Carney, Michel Lagarde, Suketu Upadhyay | Not described in the published record |
| Audit; CGNC; Nominating and Governance | Not published | Lloyd Carney | Not described in the published record |
| Audit; MDCC; Compensation | Not published | Diana McKenzie, Suketu Upadhyay | Not described in the published record |
| CGNC | Not published | Alan Garber, Lloyd Carney, Sangeeta Bhatia | Not described in the published record |
| CGNC; Nominating and Governance | Not published | Alan Garber, Sangeeta Bhatia | Not described in the published record |
| Compensation | Not published | Diana McKenzie, Jennifer Schneider, Suketu Upadhyay | Not described in the published record |
| MDCC | Not published | Diana McKenzie, Jennifer Schneider, Suketu Upadhyay | Not described in the published record |
| MDCC; Compensation | Not published | Jennifer Schneider | Not described in the published record |
| Nominating and Governance | Not published | Alan Garber, Lloyd Carney, Sangeeta Bhatia | Not described in the published record |
Committee RecordAudit: Chair not stated; Members Diana McKenzie; Lloyd Carney; Michel Lagarde; Suketu Upadhyay
Committee AppointmentDiana McKenzie: member, Audit
Committee AppointmentLloyd Carney: member, Audit
Committee AppointmentMichel Lagarde: member, Audit
Committee AppointmentSuketu Upadhyay: member, Audit
Committee RecordCGNC: Chair not stated; Members Alan Garber; Lloyd Carney; Sangeeta Bhatia
Committee AppointmentAlan Garber: member, CGNC
Committee AppointmentLloyd Carney: member, CGNC
Committee AppointmentSangeeta Bhatia: member, CGNC
Committee RecordCompensation: Chair not stated; Members Diana McKenzie; Jennifer Schneider; Suketu Upadhyay
Committee AppointmentDiana McKenzie: member, Compensation
Committee AppointmentJennifer Schneider: member, Compensation
Committee AppointmentSuketu Upadhyay: member, Compensation
Committee RecordMDCC: Chair not stated; Members Diana McKenzie; Jennifer Schneider; Suketu Upadhyay
Committee AppointmentDiana McKenzie: member, MDCC
Committee AppointmentJennifer Schneider: member, MDCC
Committee AppointmentSuketu Upadhyay: member, MDCC
Committee RecordNominating and Governance: Chair not stated; Members Alan Garber; Lloyd Carney; Sangeeta Bhatia
Committee AppointmentAlan Garber: member, Nominating and Governance
Committee AppointmentLloyd Carney: member, Nominating and Governance
Committee AppointmentSangeeta Bhatia: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerReshma Kewalramani, M.D., Chief Executive Officer and President
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceIndex MembershipS&P 500 (SPX)
Index MembershipNasdaq-100 (NDX)
Security ListingVRTX (NASDAQ)
Index memberships2 memberships attached to a specific security and listing.Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.
SPXNDX
Source reportedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
| Index | Security | Status | Effective | Verification | Source |
|---|---|---|---|---|---|
| S&P 500 (S&P Dow Jones Indices) | NASDAQ: VRTX | current | Sep 23, 2013 | inferred | Slickcharts S&P 500 constituent table (public observation, not S&P DJI license) |
| Nasdaq-100 (Nasdaq) | NASDAQ: VRTX | current | Sep 1, 2026 | exchange verified | Nasdaq official Nasdaq-100 list-type API |
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameVERTEX PHARMACEUTICALS INC / MA
Entity StatusPublic listing published
Official Websitehttps://www.vrtx.com
Published FactUS
Published FactMA
Published FactHealthcare
Published Facthttps://www.vrtx.com
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Amit K. Sachdev, J.D.Executive Vice President, Chief Patient and External Affairs Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:20
- Charles F. Wagner, Jr.Executive Vice President, Chief Operating and Financial Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:21
- Craig B. Thompson, M.D.Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:22
- Duncan J. McKechnieExecutive Vice President, Chief Commercial Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:23
- E. Morrow Morrey Atkinson, III, Ph.D.Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Science and Manufacturing Operationscompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:24
- Jonathan Biller, J.D.Executive Vice President, Chief Legal Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:25
- Kristen C. Ambrose, CPASenior Vice President, Chief Accounting Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:26
- Mark Bunnage, D.PhilExecutive Vice President, Chief Scientific Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:27
- Ourania Nia Tatsis, Ph.D.Executive Vice President, Chief Regulatory and Quality Officercompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:28
- Reshma Kewalramani, M.D.Chief Executive Officer and Presidentcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:29
- Alan GarberDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:10
- Bruce SachsLead Independent Directorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:11
- Diana McKenzieDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:12
- Jeffrey M. LeidenChaircompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:9
- Jennifer SchneiderDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:13
- Lloyd CarneyDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:14
- Michel LagardeDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:15
- Nancy ThornberryDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:16
- Reshma KewalramaniDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:17
- Sangeeta BhatiaDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:18
- Suketu UpadhyayDirectorcompany:67a28a17-ff7a-4e42-a246-5086ab42eca9:leadership_role:19
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 26 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 6 Claims.
- E2VERTEX PHARMACEUTICALS INC / MA Form 10-K (filed 2026-02-13). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
- E3sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E9sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E10sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E11sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E12sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E13sec filing. Published Apr 3, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E14VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E15VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E16VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E17VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E18VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E19VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E20VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E21VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E22VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E23VRTX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E24board_seats. sp500-board-director-completeness-remediation-2026-05-15. Cited by 21 Claims.
- E25Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
- E26Nasdaq official Nasdaq-100 list-type API. index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Jennifer Schneider seat on Vertex Pharmaceuticals, effective 2024-01-01.
- MDCC; Compensation committee of Vertex Pharmaceuticals, effective 2024-01-01.
- Jennifer Schneider member of MDCC; Compensation, effective 2024-01-01.
- Michel Lagarde seat on Vertex Pharmaceuticals, effective 2023-01-01.
- Nancy Thornberry seat on Vertex Pharmaceuticals, effective 2023-01-01.
- Suketu Upadhyay seat on Vertex Pharmaceuticals, effective 2022-01-01.
- Suketu Upadhyay member of Audit; MDCC; Compensation, effective 2022-01-01.
- Diana McKenzie seat on Vertex Pharmaceuticals, effective 2020-01-01.
- Reshma Kewalramani seat on Vertex Pharmaceuticals, effective 2020-01-01.
- Audit; MDCC; Compensation committee of Vertex Pharmaceuticals, effective 2020-01-01.
- Diana McKenzie member of Audit; MDCC; Compensation, effective 2020-01-01.
- Lloyd Carney seat on Vertex Pharmaceuticals, effective 2019-01-01.
- Audit; CGNC; Nominating and Governance committee of Vertex Pharmaceuticals, effective 2019-01-01.
- Lloyd Carney member of Audit; CGNC; Nominating and Governance, effective 2019-01-01.
- Alan Garber seat on Vertex Pharmaceuticals, effective 2017-01-01.
- CGNC; Nominating and Governance committee of Vertex Pharmaceuticals, effective 2017-01-01.
- Alan Garber member of CGNC; Nominating and Governance, effective 2017-01-01.
- Sangeeta Bhatia seat on Vertex Pharmaceuticals, effective 2015-01-01.
- Sangeeta Bhatia member of CGNC; Nominating and Governance, effective 2015-01-01.
- Jeffrey M. Leiden seat on Vertex Pharmaceuticals, effective 2009-01-01.
- Jeffrey M. Leiden chairs board Vertex Pharmaceuticals, effective 2009-01-01.
- Bruce Sachs seat on Vertex Pharmaceuticals, effective 1998-01-01.
- Bruce Sachs lead independent director of Vertex Pharmaceuticals, effective 1998-01-01.